Dermatology Department, Naval Hospital Camp Lejeune, Camp Lejeune, North Carolina.
DermOne, LLC, West Conshohocken, Pennsylvania.
JAMA Dermatol. 2017 Aug 1;153(8):802-809. doi: 10.1001/jamadermatol.2017.2077.
The notion that systemic isotretinoin taken within 6 to 12 months of cutaneous surgery contributes to abnormal scarring or delayed wound healing is widely taught and practiced; however, it is based on 3 small case series from the mid-1980s.
To evaluate the body of literature to provide evidence-based recommendations regarding the safety of procedural interventions performed either concurrently with, or immediately following the cessation of systemic isotretinoin therapy.
A panel of national experts in pediatric dermatology, procedural/cosmetic dermatology, plastic surgery, scars, wound healing, acne, and isotretinoin was convened. A systematic PubMed review of English-language articles published from 1982 to 2017 was performed using the following search terms: isotretinoin, 13-cis-retinoic acid, Accutane, retinoids, acitretin, surgery, surgical, laser, ablative laser, nonablative laser, laser hair removal, chemical peel, dermabrasion, wound healing, safety, scarring, hypertrophic scar, and keloid. Evidence was graded, and expert consensus was obtained.
Thirty-two relevant publications reported 1485 procedures. There was insufficient evidence to support delaying manual dermabrasion, superficial chemical peels, cutaneous surgery, laser hair removal, and fractional ablative and nonablative laser procedures for patients currently receiving or having recently completed isotretinoin therapy. Based on the available literature, mechanical dermabrasion and fully ablative laser are not recommended in the setting of systemic isotretinoin treatment.
Physicians and patients may have an evidence-based discussion regarding the known risk of cutaneous surgical procedures in the setting of systemic isotretinoin therapy. For some patients and some conditions, an informed decision may lead to earlier and potentially more effective interventions.
系统使用异维 A 酸(13-顺维 A 酸)在皮肤手术后 6 至 12 个月内进行治疗,可能导致异常瘢痕形成或延迟伤口愈合,这种观念得到广泛教授和实践;然而,这一观念基于 20 世纪 80 年代中期的 3 个小病例系列研究。
评估文献资料,为同时进行或在停止全身异维 A 酸治疗后立即进行的程序干预的安全性提供循证建议。
召集了一组在小儿皮肤科、程序/美容皮肤科、整形手术、瘢痕、伤口愈合、痤疮和异维 A 酸领域的国家专家小组。对 1982 年至 2017 年发表的英文文章进行了系统的 PubMed 综述,使用了以下搜索词:异维 A 酸、13-顺维 A 酸、Accutane、视黄醇、阿维 A 酯、激光、消融性激光、非消融性激光、激光脱毛、化学换肤、磨皮术、伤口愈合、安全性、瘢痕形成、增生性瘢痕和瘢痕疙瘩。对证据进行了分级,并获得了专家共识。
32 篇相关出版物报告了 1485 例手术。目前没有足够的证据支持为正在接受或最近完成异维 A 酸治疗的患者推迟手动磨皮术、浅层化学换肤术、皮肤手术、激光脱毛以及分数消融性和非消融性激光手术。根据现有文献,不建议在全身异维 A 酸治疗的情况下进行机械性磨皮术和完全消融性激光治疗。
医生和患者可以就全身异维 A 酸治疗背景下皮肤手术程序的已知风险进行基于证据的讨论。对于某些患者和某些情况,知情决策可能会导致更早且潜在更有效的干预。